Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Market Analysis
  • Published:

Diabetes and obesity: the twin epidemics

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Worldwide diabetic population (in millions).

Simon Fenwick

Figure 2: Estimated financial costs of diabetes in the US.

Simon Fenwick

Figure 3: Historical and forecast growth of the global insulin market.

Simon Fenwick

Figure 4: Historical and forecasted growth of the global oral antidiabetic market.

Simon Fenwick

Figure 5: Prevalence of obesity in US adults.

Simon Fenwick

Figure 6: Rimonabant (Acomplia) looks set to grow the obesity market.

Simon Fenwick

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrew Heron.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smyth, S., Heron, A. Diabetes and obesity: the twin epidemics. Nat Med 12, 75–80 (2006). https://doi.org/10.1038/nm0106-75

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0106-75

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing